Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-FR | Version v4-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2017-08-14 | 2017-07-31 |
| Drug Identification Number | 02240351 | 02240351 |
| Brand name | INTEGRILIN | INTEGRILIN |
| Common or Proper name | Eptifibatide Injection | Eptifibatide Injection |
| Company Name | MERCK CANADA INC | MERCK CANADA INC |
| Ingredients | EPTIFIBATIDE | EPTIFIBATIDE |
| Strength(s) | 0.75MG | 0.75MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS | INTRAVENOUS |
| Packaging size | 100ML VIAL | 100ML VIAL |
| ATC code | B01AC | B01AC |
| ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Delay in shipping of the drug. | Delay in shipping of the drug. |
| Anticipated start date | 2017-08-21 | 2017-08-21 |
| Actual start date | ||
| Estimated end date | 2017-08-31 | 2017-10-20 |
| Actual end date | 2017-08-14 | |
| Shortage status | Avoided shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |